Maxim Group Reiterates $4.00 Price Target for AEterna Zentaris (AEZS)

Maxim Group set a $4.00 price target on AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research note released on Thursday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Other research analysts have also issued reports about the stock. HC Wainwright set a $3.00 price target on shares of AEterna Zentaris and gave the company a buy rating in a research report on Wednesday, November 29th. ValuEngine raised shares of AEterna Zentaris from a strong sell rating to a sell rating in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. AEterna Zentaris currently has an average rating of Hold and an average target price of $4.33.

AEterna Zentaris (NASDAQ:AEZS) opened at $2.45 on Thursday. AEterna Zentaris has a 12-month low of $0.78 and a 12-month high of $4.25. The firm has a market cap of $44.39, a PE ratio of -1.35 and a beta of 0.87.

An institutional investor recently raised its position in AEterna Zentaris stock. JPMorgan Chase & Co. boosted its stake in AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) by 451.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 56,800 shares of the biopharmaceutical company’s stock after acquiring an additional 46,500 shares during the period. JPMorgan Chase & Co. owned 0.35% of AEterna Zentaris worth $120,000 as of its most recent filing with the SEC. 2.01% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This report was published by Community Financial News and is owned by of Community Financial News. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at

AEterna Zentaris Company Profile

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

What are top analysts saying about AEterna Zentaris? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AEterna Zentaris and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit